Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Every lot tested by Janoshik Analytical
Cart
Your cart is empty
Find
Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Your cart is empty
Pan-ERR agonist · lyophilized vial
Also known as ERR pan-agonist 332
A synthetic pan-agonist of the estrogen-related receptors (ERR alpha, beta and gamma). Supplied as a lyophilized powder for research purposes only.
Catalog opens shortly. Leave your address and we will ping you the moment this compound is orderable.
Tested lot by lot at ≥99% purity. The Janoshik certificate for your lot is emailed with the order.
Everything Valtrax Research ships is bench material for in-vitro work. None of it is a drug, a supplement, a cosmetic, or a medical device, and none of it is intended for human or animal use, ingestion, or administration. Placing an order is your confirmation that you are a qualified researcher buying for lawful research, under every Canadian law and regulation that applies to you.
A hydrazide small molecule — no peptide backbone anywhere in it — that switches on all three estrogen-related receptors, ERRα, ERRβ, and ERRγ. These are orphan nuclear receptors: they sit at the head of oxidative metabolism and mitochondrial gene programs but have no known circulating ligand to switch them on, so a synthetic agonist is the only direct way in.
The program that gene set drives overlaps substantially with what endurance training turns on, which is where the "exercise mimetic" label in the literature comes from. This is the lyophilized vial presentation; the same compound is also stocked as a capsule.
The organizing question is whether switching the ERR axis on pharmacologically reproduces part of the training-adaptation state. Studies read the compound through mitochondrial biogenesis markers, fatty-acid oxidation, exercise capacity, and whole-animal energy expenditure, with skeletal muscle and adipose tissue as the primary systems.
The compound occupies the ERR ligand pocket and stabilizes the receptors in their active conformation. What follows downstream is transcription of the oxidative program: fatty-acid oxidation genes and the machinery of mitochondrial biogenesis. Because ERRα, β, and γ are all engaged, the reported effects are read as a pan-receptor response rather than an isoform-specific one.
Published work describes raised energy expenditure, a shift toward oxidative metabolism in skeletal muscle and adipose models, and acute exercise-like responses that depend on ERRα being present. Later chemistry has pushed the scaffold further, producing orally active analogues such as SLU-PP-915.
The molecule came out of a Saint Louis University medicinal-chemistry effort to find direct ERR agonists — a hard target precisely because these receptors are orphans. Simple phenol-amide scaffolds were built and screened until compounds emerged that could engage and activate the receptor.
From there the work moved into whole-animal metabolism: an acute, ERRα-dependent aerobic exercise response, then relief of metabolic-syndrome phenotypes. The compound has since become the reference tool for asking what pharmacological ERR activation actually does, and it now appears in anti-doping analytical literature as a detection target.
Lin, H. et al. (2018). Design, synthesis, and evaluation of simple phenol amides as ERRγ agonists.
PubMedBillon, C. et al. (2023). Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.
PubMedBillon, C. et al. (2024). A Synthetic ERR Agonist Alleviates Metabolic Syndrome.
PubMedIndependent Janoshik verification of identity, purity, and net content accompanies every order as a per-lot certificate.
Janoshik Analytical, a laboratory Valtrax does not own, runs the testing — identity by mass spectrometry, purity by RP-HPLC at ≥99%. The certificate covering the lot you receive is also emailed with your order.
Same Shelf
